USE OF PNEUMOLYSIN PEPTIDES AS ANTAGONISTS AGAINST TOLL-LIKE RECEPTOR 4 AND METHODS OF TREATING TOLL-LIKE RECEPTOR 4 RELATED DISEASES

The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist..

Medienart:

Patent

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Europäisches Patentamt - (2023) vom: 06. Dez. Zur Gesamtaufnahme - year:2023

Sprache:

Englisch

Beteiligte Personen:

CHONG PELE CHOI-SING [VerfasserIn]
SIU LEUNG-KEI [VerfasserIn]
CHANG FENG-YEE [VerfasserIn]
LENG CHIH-HSIANG [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
bio
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
C12N: Microorganisms or enzymes; compositions thereof; pr (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2023-12-06, Last update posted on www.tib.eu: 2024-02-23, Last updated: 2024-03-01

Patentnummer:

EP3426677

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA006729584